Table 1.
Clinical, pathologic, and treatment characteristics of patients with triple-negative breast cancer treated with neoadjuvant hemotherapy
| Residual disease (n = 661) | Pathologic complete response (n = 316) | P value | |
|---|---|---|---|
| Age at diagnosis (years) | 0.968 | ||
| Mean (SD) | 50.5 (12.4) | 50.4 (13.1) | |
| Median (min, max) | 50.3 (21.0, 83.3) | 50.3 (24.5, 83.4) | |
| Sex assigned at birth, % | 1 | ||
| Female | 659 (99.7) | 316 (100) | |
| Male | 2 (0.3) | 0 (0) | |
| Race, % | 0.758 | ||
| Asian or Pacific Islander | 30 (4.5) | 18 (5.7) | |
| Black or African American | 88 (13.3) | 44 (13.9) | |
| Caucasian | 506 (76.6) | 240 (75.9) | |
| Other | 27 (4.1) | 12 (3.8) | |
| Unknown/not reported | 10 (1.5) | 2 (0.6) | |
| Germline status, % | 0.001 | ||
| Known BRCA1/BRCA2 mutation | 79 (12.0) | 63 (19.9) | |
| No mutation | 422 (63.8) | 175 (55.4) | |
| Not tested | 92 (13.9) | 32 (10.1) | |
| Other mutation | 24 (3.6) | 17 (5.4) | |
| Missing | 44 (6.7) | 29 (9.2) | |
| Clinical T-stage at diagnosis, % | <0.001 | ||
| T0 | 6 (0.9) | 9 (2.8) | |
| T1 | 93 (14.1) | 95 (30.1) | |
| T2 | 367 (55.5) | 155 (49.1) | |
| T3 | 113 (17.1) | 24 (7.6) | |
| T4 | 80 (12.1) | 32 (10.1) | |
| TX | 2 (0.3) | 1 (0.3) | |
| Clinical N-stage at diagnosis, % | 0.031 | ||
| N0 | 309 (46.7) | 180 (57.0) | |
| N1 | 243 (36.8) | 89 (28.2) | |
| N2 | 46 (7.0) | 19 (6.0) | |
| N3 | 62 (9.4) | 28 (8.9) | |
| NX | 1 (0.2) | 0 (0) | |
| AJCC clinical stage at diagnosis, % | <0.001 | ||
| Stage IA | 50 (7.6) | 56 (17.7) | |
| Stage IB | 4 (0.6) | 5 (1.6) | |
| Stage IIA | 242 (36.6) | 115 (36.4) | |
| Stage IIB | 154 (23.3) | 64 (20.3) | |
| Stage IIIA | 81 (12.3) | 19 (6.0) | |
| Stage IIIB | 64 (9.7) | 29 (9.2) | |
| Stage IIIC | 66 (10.0) | 28 (8.9) | |
| Histologic type, % | 0.095 | ||
| Invasive ductal | 610 (92.3) | 299 (94.6) | |
| Invasive lobular | 3 (0.5) | 4 (1.3) | |
| Mixed ductal and lobular | 12 (1.8) | 1 (0.3) | |
| Other | 35 (5.3) | 12 (3.8) | |
| Unknown | 1 (0.2) | 0 (0) | |
| Hormone receptor status at diagnosis, % | 0.968 | ||
| Negative | 544 (82.3) | 259 (82.0) | |
| Low | 117 (17.7) | 57 (18.0) | |
| HER2 status at diagnosis, % | 0.890 | ||
| IHC score 0 | 397 (60.1) | 192 (60.8) | |
| Low | 264 (39.9) | 124 (39.2) | |
| RCB class, % | - | ||
| RCB 0 | 0 (0) | 316 (100) | |
| RCB-I | 94 (14.2) | - | |
| RCB-II | 304 (46.0) | - | |
| RCB-III | 146 (22.1) | - | |
| Cannot be calculated/unknown/not documented | 117 (17.7) | - | |
| Neoadjuvant anthracycline + taxane ± platinum, % | 0.182 | ||
| Yes | 527 (79.7) | 264 (83.5) | |
| No | 134 (20.3) | 52 (16.5) | |
| Breast surgery, % | 0.055 | ||
| Breast conserving therapy | 241 (36.5) | 130 (41.1) | |
| Mastectomy | 417 (63.1) | 181 (57.3) | |
| Axillary surgery only | 3 (0.5) | 5 (1.6) | |
| Axillary surgery, % | <0.001 | ||
| Only SLNB | 269 (40.7) | 168 (53.2) | |
| Only ALND | 244 (36.9) | 73 (23.1) | |
| Both (SLNB followed by ALND) | 60 (9.1) | 0 (0) | |
| No axillary surgery | 4 (0.6) | 2 (0.6) | |
| Unknown | 84 (12.7) | 73 (23.1) | |
| Radiation therapy receipt, % | 0.034 | ||
| No | 154 (23.3) | 94 (29.7) | |
| Yes | 505 (76.4) | 222 (70.3) | |
| Unknown | 2 (0.3) | 0 (0) | |
Bold P value indicates nominal P < 0.05.
AJCC, American Joint Committee on Cancer; ALND, axillary lymph node dissection; IHC, immunohistochemistry; RCB, residual cancer burden; SD, standard deviation; SLNB, sentinel lymph node biopsy.